"Prolonged treatment with ddI (didanosine, Videx) is the sole factor significantly associated with the development of noncirrhotic portal hypertension in HIV-positive individuals, Swiss investigators report in the August 15th edition of Clinical Infectious Diseases.
"The investigators recommend that 'a high index of suspicion is needed in ddI-exposed patients with clinical signs of liver disease'."
Read more in Aidsmap, July 29, 2009.
0 comments:
Post a Comment